Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/12/2025

Reversal Agent Dosing for IV Sedation

Introduction to Reversal Agents

  • The American Society of Anesthesiologists recommends that both reversal agents be immediately available whenever benzodiazepines or opioids are used for sedation, to decrease adverse outcomes 2

Naloxone Dosing for Opioid Reversal

  • Adults <20 kg should receive 0.1 mg/kg IV/IM of naloxone, while adults ≥20 kg should receive 2 mg IV/IM, with repeat doses every 2 minutes as needed for persistent respiratory depression 1
  • When reversing therapeutic opioid sedation, use lower doses (1-15 mcg/kg) of naloxone to avoid complete reversal of analgesia, preventing acute pain, hypertension, tachycardia, or pulmonary edema from sudden opioid reversal 1, 2
  • Patients should be observed for at least 2 hours after the last naloxone dose for recurrence of respiratory depression, as naloxone's duration of action (~1 hour) is shorter than most opioids 1

Critical Safety Considerations

  • Before or concurrent with pharmacologic reversal, always stimulate the patient to breathe deeply, provide supplemental oxygen, and administer positive-pressure ventilation if spontaneous ventilation is inadequate, as reversal agents are adjuncts, not replacements, for airway management 2
  • Flumazenil is contraindicated in tricyclic antidepressant overdose and should be used with extreme caution in patients with seizure disorders treated with benzodiazepines, as it may induce seizures or arrhythmias 3
  • Naloxone may induce acute withdrawal in opioid-dependent patients and cause pain, hypertension, tachycardia, or pulmonary edema, and should not be used in neonates whose mothers have long-term opioid use due to the risk of seizures/acute withdrawal 1, 2

Administration Technique

  • Maintain IV access throughout sedation and until the patient is no longer at risk for cardiorespiratory depression, and administer reversal agents through a freely running IV infusion into a large vein to minimize injection site pain 2
  • Continuous observation for at least 2 hours after the last reversal agent dose is necessary, with monitoring of vital signs, oxygen saturation, and level of consciousness 1, 2